The CRCTU specialises in cancer trials but also has a portfolio of early phase non-cancer trials (delivered via the D3B team based in the Institute of Translational Medicine). The Unit runs trials for both adults and children, being the National Children’s Cancer Trials Unit. The CRCTU also hosts several national cancer programmes including: the Trial Acceleration Program (TAP) funded by Bloodwise; the IMPACT programme funded by Anthony Nolan, Leuka and NHS Blood and Transplant; and is the clinical trials unit for the Birmingham Experimental Cancer Centre (ECMC). The Unit also plays a key role in the delivery of trials for the Birmingham NIHR Biomedical Research Centre (BRC), Midlands & Wales Advanced Therapy Treatment Centre (MW-ATTC), and Arthritis Trials Acceleration Programme (A-TAP).
CRCTU works in partnership with the Birmingham Clinical Trials Unit (BCTU) to deliver the Birmingham Surgical Trials Consortium (BiSTC).
The CRCTU has over 40 years experience of collaborating with clinicians in designing efficient and innovative clinical trials, supporting successful funding applications and delivering regulatory compliant academic investigator-initiated and led clinical trials to a high standard of Good Clinical Practice (GCP). The Unit undertakes all tasks required to deliver a clinical trial from conception to completion (see Resources and Services).
The Unit has experience of running trials of:
- Investigational medicinal products (CTIMPS)
- Advanced therapy medicinal products (ATIMPs)
The CRCTU is able to harness what is a key asset of Birmingham its single Biomedical Campus which encompasses: the CRUK Birmingham Cancer Centre; the Birmingham Experimental Cancer Medicine Centre; the Birmingham Health Partners Institute of Translational Medicine; the Human Biomaterials Research Centre; the West Midlands Regional Genetics Laboratory; the adult and paediatric NIHR Welcome Trust Clinical Research Facilities; University Hospitals NHS Foundation Trust; and Birmingham Women and Children’s Hospital.